Interestingly, the APOA4 273–283 fragment demonstrated pathological stage-dependent up-regulation in lung cancer patients' sera, while the two-residue longer fragment APOA4 271–283 was significantly decreased in lung cancer samples (Fig. 6A). This evidence concerns the gene APOA4 and lung carcinoma.